A team of Stanford University scientists think they have found a potential reason why GlaxoSmithKline's now-withdrawn flu shot Pandemrix was associated with a spike in narcolepsy cases.
In 2013, scientists and governments estimated that there were close to 800 narcolepsy cases tied to GlaxoSmithKline's swine flu vaccine, Pandemrix. And now, a team of scientists at Stanford University believes they have discovered the link.
The API of GlaxoSmithKline's HIV therapy Tivicay (dolutegravir) will be made in China by Shanghai-based Desano Pharmaceuticals under a deal with the British drug maker's ViiV Healthcare arm, according to a press release.
In 2013, GlaxoSmithKline CEO Andrew Witty pledged to end doctor payments by 2016 as part of an effort to clean up the company's image. But so far, little has changed in that department.
In the post- FTC v. Actavis world, cash doesn't have to change hands for a pay-for-delay deal to fall afoul of antitrust law. That's becoming clear as court rulings pile up. And a new U.S. appeals court decision specifically addresses a branded drugmaker's agreement not to launch an authorized generic of its branded drug.
The CDC's Advisory Committee for Immunization Practices gave the go-ahead for wider use of meningitis B vaccines, but stopped short of a universal recommendation, not the result many--including GlaxoSmithKline and Pfizer--were hoping to see.
The CDC's Advisory Committee on Immunization Practices (ACIP) voted on Wednesday to expand its recommendation for meningitis B vaccines, but it wasn't the broad recommendation that many were hoping to see.
In a move to allay antitrust concerns, GlaxoSmithKline is selling two of its meningitis vaccines to Big Pharma peer Pfizer. The move comes after Glaxo acquired the bulk of Novartis' vaccines portfolio, which catapulted it to the No. 1 spot in the global vaccines market.
FierceBiotech Radio is back with a two-part special from the BIO conference in Philadelphia.
At the 2015 BIO conference in Philadelphia, FierceBiotech Editor-in-Chief John Carroll moderates a discussion on the future of cancer R&D, featuring leaders from AstraZeneca, Juno Therapeutics, Merck, Johnson & Johnson and GlaxoSmithKline.